Markets

Insider Trading

Hedge Funds

Retirement

Opinion

25 Richest Billionaires in Healthcare Industry

In this article, we discuss the 25 richest billionaires in healthcare industry. To skip the detailed analysis of the healthcare industry, go directly to the 5 Richest Billionaires in Healthcare Industry.

Global Healthcare Industry Outlook and Trends

The global healthcare industry is going through a massive transition amid technological advancements, changing patient needs, and demographic shifts. According to Deloitte, the global healthcare market is growing rapidly, valued at around $8.5 trillion as of 2020. Artificial intelligence (AI) has had the most significant impact on the healthcare industry from streamlining processes to sustainability practices and remote technologies for care delivery to innovative strategies to address rising costs. As per a research study by PubMed Central, AI has massively influenced the radiology sector with the first use of AI in image acquisition and storage. Today, computer-assisted diagnosis (CAD) is helping radiology by providing accuracy and consistency of diagnostic imaging. According to the data by Maximize Market Research Pvt Ltd., the computer-aided detection market was valued at around $836.5 billion in 2023 and is projected to grow to $1.24 billion by 2030, growing at a compound annual growth rate of 5.78% from 2024 to 2030.

The data from the American Cancer Society (ACS) shows that an estimated 43,250 women suffered severely from breast cancer, while 287,850 new cases of invasive breast cancer emerged. Almost 83% of women aged 50 and above suffered from new instances of invasive breast cancer and 91% of all breast cancer-related deaths. In this aspect, CAD plays an important role as it helps in cancer detection and treatment.

The US healthcare market is one of the largest in the world. According to a report by McKinsey & Company, the healthcare profit pools in the US are expected to grow at a compound annual growth rate of 7% from $583 billion in 2022 to $819 billion in 2027. The government healthcare segments are estimated to be 65% larger than commercial segments by 2027. In addition, the US healthcare sector’s EBITDA is projected to reach $366 billion by 2027. As per McKinsey, the US health system will potentially increase reimbursement in the high single digits to cover up cost inflation in recent years.

On the other hand, Europe’s healthcare is diverse with countries managing their systems independently. In our article about the 20 countries with the best healthcare in 2024, we addressed that healthcare spending in the European Union was reported to be around €1.5 trillion in 2022. Major economies such as Germany and France spend around 11% of their GDP on healthcare. France, Armenia, Palau, the US, and Tuvalu are some of the leading countries that spend the most on healthcare.

Big Players in the Healthcare Industry

HCA Healthcare, Inc. (NYSE:HCA), BioNTech SE (NASDAQ:BNTX), and Hansoh Pharmaceutical Group Company Limited (HKG:3692) are some of the leading companies in the healthcare industry. Let’s discuss some recent updates from them.

HCA Healthcare, Inc. (NYSE:HCA) is one of the leading American for-profit operators of healthcare facilities. On April 19, HCA Healthcare, Inc. (NYSE:HCA) announced that two large multi-state studies found a highly effective procedure to ameliorate antibiotic selection for patients suffering from pneumonia or urinary tract infections (UTI). The studies were carried out by HCA Healthcare, Inc. (NYSE:HCA) in collaboration with Harvard Pilgrim Health Care Institute, and the University of California. As per the studies, over 220,000 patients were observed in pneumonia or UTI trials in 59 HCA Healthcare, Inc. (NYSE:HCA) hospitals.

BioNTech SE (NASDAQ:BNTX) is one of the top German biotechnology companies, famously known for collaborating with Pfizer Inc. (NYSE:PFE) for the first approved COVID-19 vaccine. On April 7, BioNTech SE (NASDAQ:BNTX) reported the three-year follow-up on the Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran. During the Phase 1 trial, the data shows that 8 out of 16 patients suffering from pancreatic ductal adenocarcinoma (PDAC) showed a persistent immune response to autogene cevumeran. Here is what the BioNTech SE’s (NASDAQ:BNTX) chief medical officer, Özlem Türeci, said:

“These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need. The results indicate that our uridine mRNA-LPX technology can promote activation of cytotoxic T cells that may help to eliminate residual tumor foci at early stages of the disease to delay or prevent recurrence. Our ongoing Phase 2 trial with Genentech aims to confirm these findings on benefit for patients with PDAC compared with the current standard of care treatment in the post-surgical, adjuvant setting in a larger patient population. We remain committed to our vision of personalized cancer medicine and aim to help advance the standard of care for many patients.”

Hansoh Pharmaceutical Group Company Limited (HKG:3692) is one of the leading pharmaceutical companies in China. On March 14, the company announced that it has further expanded its partnership with Biotheus Inc., following its current collaboration since 2022. Through the continuity of this new strategic alliance, Biotheus will grant a license to Hansoh Pharmaceutical Group Company Limited (HKG:3692) to develop anti-EGFR/cMet bispecific antibody-drug conjugates. Hansoh Pharmaceutical Group Company Limited (HKG:3692) will obtain exclusive worldwide rights to develop, produce, and commercialize the ADC Product. Hansoh Pharmaceutical Group Company Limited (HKG:3692) will make an upfront payment of RMB 5 billion for the agreement and also pay success-based milestones and royalties for ADC Product net sales.

Healthcare is one of the fastest-growing industries in the world and healthcare firms have a big role to play. Now, let’s take a look at the 25 richest billionaires in the healthcare industry.

A healthcare professional using a digital device to provide a health risk assessment to a patient.

Our Methodology

We gathered the data for the 25 richest billionaires in the healthcare industry from the Forbes Real Time Billionaires Index. The list of billionaires from the healthcare industry is ranked in ascending order of billionaires’ net worths, as of April 16.

25 Richest Billionaires in Healthcare Industry

25. Alain Merieux

Net Worth: $6.7 Billion

Alain Merieux founded bioMérieux S.A. (EPA:BIM), a multinational biotechnology firm. Merieu is chairman of Institut Merieux, a medicine and public health conglomerate. Alain Merieux has a net worth of around $6.7 billion and ranks 25th among the richest billionaires in the healthcare industry.

24. Niels Peter Louis-Hansen

Net Worth: $6.7 Billion

Niels Peter Louis-Hansen serves the healthcare firm, Coloplast A/S (CPH:COLO-B), as the deputy chairman. Hansen owns one-fifth of Coloplast A/S (CPH:COLO-B) and is its largest shareholder. Niels Peter Louis-Hansen is one of the richest billionaires in the healthcare industry.

23. Seo Jung-jin

Net Worth: $6.9 Billion

Seo Jung-jin co-founded the biopharmaceutical firm, Celltrion, Inc. (KRX:068270). With a net worth of around $6.9 billion, Seo Jung-jin ranks 23rd among the richest billionaires in the healthcare industry.

22. Viktor Kharitonin

Net Worth: $6.9 Billion

In 2003, Viktor Kharitonin founded the multinational pharmaceutical firm Pharmstandard with his colleagues including Roman Abramovich and others. Viktor Kharitonin has a net worth of around $6.9 billion.

21. Reinhold Schmieding

Net Worth: $7.1 Billion

In 1981, Reinhold Schmieding founded Arthrex, an orthopedic surgical tools company. Reinhold Schmieding is one of the richest billionaires in the healthcare industry in 2024.

20. Sergio Stevanato

Net Worth: $7.1 Billion

Sergio Stevanato is chairman emeritus of the Stevanato Group S.p.A. (NYSE:STVN), a medical packaging firm. The firm was founded by Stevanato’s father Giovanni in 1949. Sergio Stevanato ranks among the richest billionaires in the healthcare industry in 2024.

19. Massimiliana Landini Aleotti 

Net Worth: $7.2 Billion

Massimiliana Landini Aleotti inherited the pharmaceutical giant Menarini from her late husband, Alberto Aleotti. With a net worth of around $7.2 billion, Massimiliana Landini ranks 19th among the richest billionaires in the healthcare industry.

18. Frederik Paulsen

Net Worth: $7.3 Billion

Frederik Paulsen inherited a fortune in drugmaker Ferring Pharmaceuticals started by his father in 1950. Frederik Paulsen has a net worth of around $7.3 billion.

17. Chen Bang

Net Worth: $7.3 Billion

Chen Bang is the chairman of Aier Eye Hospital Group Co., Ltd. (SHE:300015), the largest ophthalmology chain in China. The company runs over 800 eye hospitals and centers in China, the US, Europe, and Southeast Asia. With a net worth of around $7.3 billion, Chen Bang is one of the richest billionaires in the healthcare industry in 2024.

16. John Brown

Net Worth: $7.3 Billion

John Brown ran the multinational medical technologies firm, Stryker Corporation (NYSE:SYK) for 32 years before retiring as chairman in 2009. Brown also owns almost 5% of the stake in the firm.

15. Hasmukh Chudgar 

Net Worth: $7.7 Billion

Hasmukh Chudgar founded the multinational pharmaceutical company, Intas Pharmaceuticals, in 1977. Hasmukh Chudgar has a net worth of almost $7.7 billion and ranks 15th among the richest billionaires in the healthcare industry.

14. Ronda Stryker

Net Worth: $7.9 Billion

Ronda Stryker is the director of Stryker Corporation (NYSE:SYK) and owns a 6% stake in the company inherited from her parents. Ronda Stryker has a net worth of around $7.9 billion.

13. Xu Hang

Net Worth: $8.6 Billion

Xu Hang co-founded the medical devices supplier, Mindray Bio-Medical Electronics. Xu Hang ranks 13th among the richest billionaires in the healthcare industry.

12. Zhong Huijuan

Net Worth: $8.6 Billion

Zhong Huijuan is the chairman of Hansoh Pharmaceutical Group Company Limited (HKG:3692). Huijuan’s husband, Sun Piaoyang, is a pharmaceutical billionaire who runs Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276).

11. Pankaj Patel

Net Worth: $9 Billion

Pankaj Patel runs the Indian multinational pharmaceutical firm, Zydus Lifesciences Limited (NSE:ZYDUSLIFE). With a net worth of around $9 billion, Pankaj Patel ranks 11th among the richest billionaires in the healthcare industry.

10. Sun Piaoyang

Net Worth: $9.3 Billion

Sun Piaoyang is the CEO of Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276). Sun Piaoyang became head of the firm in 1990.

9. Andreas Struengmann 

Net Worth: $9.6 Billion

Andreas Struengmann has a net worth of around $9.6 billion. Andreas Struengmann and his brother Thomas were early backers of BioNTech SE (NASDAQ:BNTX).

8. Thomas Struengmann 

Net Worth: $9.6 Billion

In 1986, Thomas Struengmann along with his brother Andreas co-founded generic drugmaker Hexal. The brothers later sold the company to Novartis AG (NYSE:NVS) in 2005 for around $7 billion. Thomas Struengmann ranks eighth among the richest billionaires in the healthcare industry.

7. Jiang Rensheng 

Net Worth: $9.6 Billion

Jiang Rensheng is the chairman of the vaccine firm Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122). In 2023, Rensheng took his antibody drugmaker company, Chongqing Genrix Biophrmctcl Co., Ltd. (SHA:688443), public in Shanghai.

6. Carl Cook

Net Worth: $10.2 Billion

Carl Cook is one of the richest billionaires in the healthcare industry. In 2011, Carl Cook became the CEO of his parents’ medical device manufacturer, Cook Group.

Click to continue reading and see the 5 Richest Billionaires in Healthcare Industry.

Suggested articles:

Disclosure. None. 25 Richest Billionaires in Healthcare Industry is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…